Lilly Is Latest Target Of Philadelphia U.S. Attorney's Rx Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Investigation into Lilly's marketing and promotional practices is focused on Evista, Prozac and Zyprexa, company says. Subpoenas may reflect Philadelphia prosecutor's interest in PBMs and Federal Employee Health Benefits Program.
You may also be interested in...
AstraZeneca Rx Promotions Subject Of U.S. Attorney Investigation
The Los Angeles U.S. Attorney’s Office is examining the company’s local field promotions.
AstraZeneca Rx Promotions Subject Of U.S. Attorney Investigation
The Los Angeles U.S. Attorney’s Office is examining the company’s local field promotions.
Lilly Rebates Prompt U.S. Attorney Investigation
The Philadelphia U.S. Attorney’s office is investigating Medicaid best price reporting for Zyprexa and several other Lilly products.